Status: Recruiting
Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
This is a phase II study that will examine the immunogenicity of the Shingrix vaccine in patients following an allogeneic stem cell transplant.
Participants needed: 100
Trial details
Phase: Phase 2Biological sex: AllType: InterventionalSponsor: Loyola UniversityUpdated: Mar 8, 2023Locations: 1
Eligibility criteria
Age ≥18 years [+8]
Patients who had zoster after an allogeneic transplant and prior to enrollment [+6]